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Since 1918, the association of coinfection with 
S aureus has been a persistent theme in the literature 
on inﬂ uenza.9 Defects in bacterial killing by alveolar 
macrophages, neutrophil recruitment and function, 
and T-cell-dependent immune responses predispose 
the inﬂ uenza-infected lung to S aureus superinfection.10 
In a meta-analysis of studies with enrolment during 
1999–2012, the authors found that S aureus was the 
cause of 28% of bacterial coinfections with inﬂ uenza.11 
In 33 US hospitals in 2013–14, we found that S aureus 
accounted for more than 36% of bacterial coinfections 
of severe inﬂ uenza, and was the leading cause of such 
complications.12 Aliberti and colleagues did not record 
which patients had a concordant inﬂ uenza infection and 
bacterial community-acquired pneumonia. Inﬂ uenza 
coinfection in their study therefore might have been an 
unaccounted confounding variable biasing the geographic 
variability reported in the prevalence of S aureus. 
Further research is necessary to delineate the 
worldwide molecular epidemiology of S aureus and 
MRSA pneumonia and the clinical and microbial risk 
factors that are responsible for the great disparity in 
their prevalence noted by Aliberti and colleagues in their 
impressively large and geographically diverse study. 
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Unravelling mucosal immunity to poliovirus
From an immunological perspective, the battle to 
eradicate polio is one of blood and guts. Induction 
of circulating poliovirus antibodies in blood is 
essential to block the spread of viruses to the CNS and 
thereby protect against paralytic disease. However, as 
eradication draws closer, the induction of immunity in 
the gut mucosa is becoming an ever-greater concern. 
Mucosal immunity is key to halting the spread 
of poliovirus from person to person, and thereby 
condemning the virus to extinction.
A major transition in the way that polio is immunised 
against is underway across the world. In April, 2016, 
use of the trivalent attenuated oral poliovirus vaccine 
(tOPV), which targets each of the three poliovirus 
serotypes, was replaced by a bivalent formulation 
targeting serotypes 1 and 3 (bivalent oral poliovirus 
vaccine; bOPV)—step one in the globally synchronised 
withdrawal of oral poliovirus vaccines that must occur 
to prevent polio caused by vaccine-derived poliovirus. 
To ﬁ ll the gap in serotype 2 immunity, at least one 
dose of inactivated poliovirus vaccine (IPV) has been 
introduced into routine immunisation programmes in 
most countries that use oral poliovirus vaccines. Thus, 
in a matter of months, more than 100 countries have 
shifted from a routine schedule relying solely on tOPV to 
a mixed schedule of bOPV and IPV. 
A major concern accompanying these shifts in 
vaccination policy is their implications for mucosal 
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immunity. Although oral poliovirus vaccine is known to 
induce a robust mucosal response (albeit one that wanes 
over time), IPV is only able to do so if individuals have 
been primed by previous exposure to live poliovirus 
(vaccine or wild-type).1 In The Lancet Infectious Diseases, 
Peter F Wright and colleagues2 report on a study seeking 
to clarify the impact of changes in routine vaccination 
on mucosal immunity to poliovirus. Infants from 
several countries in Latin America were immunised 
at 6, 10, and 14 weeks of age with bOPV, tOPV, or a 
mixed schedule of bOPV and IPV.3 Mucosal immunity 
to serotype 2 poliovirus was assessed at 18 weeks 
by measuring poliovirus-speciﬁ c antibodies in stool 
samples and shedding of poliovirus after administration 
of a challenge dose of monovalent serotype 2 (mOPV2) 
oral poliovirus vaccine. Although oral poliovirus vaccine 
challenge is the gold standard for measurement of 
mucosal poliovirus protection, attenuated vaccine 
viruses might fail to replicate for several reasons, 
including interference by concurrent enteroviruses,4 so 
it is by no means perfect.
The assessment of antibodies in mucosal samples is 
fraught with complications, including cellular toxicity, 
dilution eﬀ ects during sample collection, and the 
breakdown of immunoglobulin by proteolytic enzymes. 
Despite these constraints, Wright and colleagues 
successfully quantiﬁ ed the neutralisation titre of 
stool samples using serotype 2 polio pseudoviruses 
(comprising luciferase-encoding replicons surrounded 
by poliovirus capsid proteins). Neutralisation titre at 
the time of challenge was inversely correlated with 
the quantity of serotype 2 virus shedding 7 days later, 
supporting the use of this assay as a measure of mucosal 
protection. A similar association was not noted for 
poliovirus-speciﬁ c IgA in stool, despite these antibodies 
being the probable mechanistic correlate of protection 
at the gut mucosa. 
There are alternative approaches to measure mucosal 
immunity. A study5 of children in India showed that 
the number of circulating poliovirus-speciﬁ c antibody-
secreting cells expressing the gut-homing integrin 
α4β7 could be a correlate of mucosal immunity. And in 
populations immunised with oral poliovirus vaccines, 
serum neutralising-antibody titres are a reasonable 
correlate of mucosal protection and are used by the 
Global Polio Eradication Initiative to monitor progress in 
high-risk areas.6
The study by Wright and colleagues also draws 
attention to one of the major obstacles currently facing 
the polio endgame: the deﬁ cits in serotype 2 mucosal 
immunity after a mixed schedule of bOPV and IPV. Of 
87 infants who received this schedule, 53 (61%) shed 
virus 7 days after mOPV2 challenge, compared with just 
two (5%) of 38 infants who were vaccinated with tOPV. 
As the tOPV era becomes more and more distant, the 
cohort of infants who have never been exposed to live 
serotype-2 poliovirus and thus lack mucosal immunity 
will expand. 
Serotype 2 polioviruses will hopefully be consigned 
to the history books soon. However, the resurfacing 
in August, 2016, of polio in Nigeria as a result of 
wild serotype 1 virus after more than 2 polio-free 
years provides a stark warning against complacency.7 
Comprehensive surveillance of children with acute ﬂ accid 
paralysis and environmental samples is undoubtedly 
crucial to the success of the polio endgame. Even with 
robust surveillance, a pivotal question remains: how long 
has to pass without detection of polio before it can be 
concluded that the disease is gone for good?
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